| Literature DB >> 23075516 |
Mathieu Métifiot1, Kasthuraiah Maddali, Barry C Johnson, Stephen Hare, Steven J Smith, Xue Zhi Zhao, Christophe Marchand, Terrence R Burke, Stephen H Hughes, Peter Cherepanov, Yves Pommier.
Abstract
On the basis of a series of lactam and phthalimide derivatives that inhibit HIV-1 integrase, we developed a new molecule, XZ-259, with biochemical and antiviral activities comparable to raltegravir. We determined the crystal structures of XZ-259 and four other derivatives in complex with the prototype foamy virus intasome. The compounds bind at the integrase-Mg(2+)-DNA interface of the integrase active site. In biochemical and antiviral assays, XZ-259 inhibits raltegravir-resistant HIV-1 integrases harboring the Y143R mutation. Molecular modeling is also presented suggesting that XZ-259 can bind in the HIV-1 intasome with its dimethyl sulfonamide group adopting two opposite orientations. Molecular dynamics analyses of the HIV-1 intasome highlight the importance of the viral DNA in drug potency.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23075516 PMCID: PMC3548936 DOI: 10.1021/cb300471n
Source DB: PubMed Journal: ACS Chem Biol ISSN: 1554-8929 Impact factor: 5.100